Calcium channel blockers (CCBs) are the choice of therapy for post-stroke patients. A large-scale prospective study of 2667 post-stroke hypertensive patients treated with cilnidipine assessed BP control and adverse reactions in the patients. Cilnidipine treatment led to a reduction in both clinic and home BP 2 months after treatment initiation. The decreased BP was maintained until the end of 12 months of observation. The proportion of patients with well controlled clinic BP (<140/90 mmHg) rose from 21.5% to 65.3% with cilnidipine treatment, with no differences seen in effectiveness across the various clinical subtypes of stroke. In all, 346 adverse events occurred, with an overall incidence of 8.9% (238 of 2667 patients). Cilnidipine effectively treated uncontrolled BP and was well tolerated in post-stroke hypertensive patients in a real-world clinical setting. The results were published in Clinical and Experimental Hypertension.